• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
Moxifloxacin Free Base

Moxifloxacin Free Base

Product ID M5793
Cas No. 151096-09-2
Purity ≥98%
Product Unit SizeCostQuantityStock
100 mg $142.80 In stock
500 mg $499.50 In stock
1 g $642.10 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

Moxifloxacin is a fluoroquinolone antibiotic commonly used to treat ocular infections such as bacterial conjunctivitis as well as sinus and lung infections such as pneumonia. Moxifloxacin displays antibacterial efficacy against both gram negative and gram positive bacteria, preventing DNA synthesis in bacterial pathogens by inhibiting topoisomerase IV and bacterial DNA gyrase. This compound is currently being examined as a conjunctive therapy with anticancer agents against several forms of cancer due to its topoisomerase II inhibition. Combining moxifloxacin with anticancer agents yields a cytotoxic drug sparing effect due to the synergism of the mechanisms of action between moxifloxacin and the anticancer drugs.

Product Info

Cas No.

151096-09-2

Purity

≥98%

Formula

C21H24FN3O4

Formula Wt.

401.43

IUPAC Name

7-[(4aS,7aS)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3, 4-b]pyridin-6-yl]-1-cyclopropyl-6-fluoro-8-methoxy-4-oxoquinoline-3- carboxylic acid

Appearance

Yellow Solid

Shipping and Storage

Store Temp

4°C

Ship Temp

Ambient

Downloads

MSDS

M5793 MSDS PDF

Info Sheet

M5793 Info Sheet PDF

References

Wohlkonig A, Chan PF, Fosberry AP, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010 Sep;17(9):1152-3. PMID: 20802486.

Reuveni D, Halperin D, Shalit I, et al. Moxifloxacin enhances etoposide-induced cytotoxic, apoptotic and anti-topoisomerase II effects in a human colon carcinoma cell line. Int J Oncol. 2010 Aug;37(2):463-71. PMID: 20596674.

Reuveni D, Halperin D, Fabian I, et al. Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors. Biochem Pharmacol. 2010 Apr 15;79(8):1100-7. PMID: 20025849.

Laponogov I, Sohi MK, Veselkov DA, et al. Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases. Nat Struct Mol Biol. 2009 Jun;16(6):667-9. PMID: 19448616.

Stroman DW, Dajcs JJ, Cupp GA, et al. In vitro and in vivo potency of moxifloxacin and moxifloxacin ophthalmic solution 0.5%, a new topical fluoroquinolone. Surv Ophthalmol. 2005 Nov;50 Suppl 1:S16-31. PMID: 16257308.

Aldred KJ, McPherson SA, Wang P, et al. Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012 Jan 10;51(1):370-381. PMID: 22126453.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • S0225

    SAG Dihydrochloride

    Smoothened agonist.
    ≥98%
  • G0244

    alpha-Galactosylceramide

    Synthetic glycolipid found in Agelas mauritanius; ...
    ≥96%
  • J889280

    JWH 015

    Cannabinoid receptor 2 selective agonist.
    ≥98%
  • P0353

    Pancreatic Polypeptide, human

    Endogenous peptide, regulates pancreatic cell sign...
    ≥98%
  • C1644

    Celecoxib

    NSAID; COX-2 inhibitor.
    ≥99%
  • G6802

    Granisetron Hydrochloride

    5-HT3 antagonist.
    ≥98%
  • I0801

    IC261

    Casein kinase 1 inhibitor.
    ≥98%
  • E4668

    ELR-510444

    Microtubule polymerization inhibitor.
    ≥98%
  • A9914

    AZD-8055

    mTOR inhibitor.
    ≥98%
  • D1627

    Dehydrocostus Lactone

    Sesquiterpene lactone found in Saussurea.
    ≥98%
  • V0274

    [Lys8]-Vasopressin

    Peptide, vasopressin analog; V1/2 agonist.
    ≥95%
  • K0144

    Kallikrein Inhibitor

    Peptide; serine protease inhibitor.
    ≥95%
  • A5326

    Aniracetam

    AMPA positive allosteric modulator, D2, 5-HT2A, nA...
    ≥98%
  • R3224

    Rigin

    Peptide, IgG derivative, tuftsin analog.
    ≥95%
  • P6850

    Prolactin-Releasing Peptide (1-31), human

    Endogenous peptide hormone, involved in hormone se...
    ≥98%
  • L1982

    Leupeptin Hemisulfate

    Protease inhibitor.
    ≥95%
  • F1895

    Fexofenadine Hydrochloride

    Histamine H1 antagonist.
    ≥98%
  • G2873

    Growth Hormone Releasing Factor, sheep

    Endogenous peptide hormone, involved in growth hor...
    ≥95%
  • B1955

    Benztropine Mesylate

    DAT inhibitor.
    ≥99%
  • R3011

    Recombinant TpN 15 protein

    Recombinant protein containing Treponema pallidum ...
    ≥95%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2025 LKT Laboratories, All Rights Reserved - Products for research use only